Literature DB >> 6599673

Primary aldosteronism is comprised of primary adrenal hyperplasia and adenoma.

E G Biglieri, C E Kater, E E Arteaga.   

Abstract

Primary aldosteronism due to primary adrenal hyperplasia (PAH) is described. Hypertension, hypokalaemia, hyperaldosteronism and renin suppression were corrected by unilateral adrenalectomy in 3/5 patients and by spironolactone treatment in 2/5. Blood pressure and hormonal parameters have remained normal for up to seven years after surgery and spironolactone management. Four patients had bilateral micro- and macronodular hyperplasia and one had unilateral hyperplasia. While hormonally and biochemically identical to patients with aldosterone producing adenoma, PAH can be distinguished from idiopathic hyperaldosteronism (adrenal hyperplasia). The inability to demonstrate a tumour by computed tomography but the presence of bilateral elevations of aldosterone concentration in adrenal venous blood identifies PAH.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6599673

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  5 in total

Review 1.  Stepped care for hypertension is dead, but what will replace it?

Authors:  J D Spence
Journal:  CMAJ       Date:  1989-05-15       Impact factor: 8.262

Review 2.  Intensive management of risk factors for accelerated atherosclerosis: the role of multiple interventions.

Authors:  J David Spence
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

3.  Physiologic tailoring of treatment in resistant hypertension.

Authors:  J David Spence
Journal:  Curr Cardiol Rev       Date:  2010-05

4.  Primary aldosteronism: difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands.

Authors:  T Jeck; B Weisser; T Mengden; L Erdmenger; S Grüne; W Vetter
Journal:  Clin Investig       Date:  1994-12

5.  New treatment options for hypertension during acute ischemic or hemorrhagic stroke.

Authors:  J David Spence
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.